The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the multidrug resistance-associated ATP-binding cassette transporter ABCG2

Ítems similars

• The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
  per: Bhullar, Jasjeet, et al.
  Publicat: (2013)
• The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms
  per: Natarajan, Karthika, et al.
  Publicat: (2012)
• The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations
  per: Mathias, Trevor J., et al.
  Publicat: (2015)
• Pharmacophore Modeling of Nilotinib as an Inhibitor of ATP-Binding Cassette Drug Transporters and BCR-ABL Kinase Using a Three-Dimensional Quantitative Structure–Activity Relationship Approach
  per: Shukla, Suneet, et al.
  Publicat: (2014)
• Renovascular hypertension from the BCR‐ABL tyrosine kinase inhibitor ponatinib
  per: Amin, Syed O., et al.
  Publicat: (2020)